trending Market Intelligence /marketintelligence/en/news-insights/trending/rkje3nrjtdfvvz6nkp9nww2 content esgSubNav
In This List

Bio-Path regains Nasdaq compliance

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Bio-Path regains Nasdaq compliance

The Nasdaq Stock Market LLC's listing qualifications department notified Bio-Path Holdings Inc. that it has regained compliance with the exchange's minimum bid price requirement.

The closing bid price of Bio-Path common stock has been at $1.00 per share or more from Feb. 9 through Feb. 23.

The Texas-based cancer drugmaker received the noncompliance notice in September 2017.